Traws Pharma, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8M | $226.0K | $226.0K | $226.0K | $226.0K | $231.0K | $2.2M | $1.2M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | $11.4M | $11.4M | $7.3M | $16.9M | $15.5M | $16.9M |
| SG&A Expense | $8.5M | $12.3M | $9.1M | $8.4M | $9.4M | $8.3M | $8.3M | $7.6M |
| Operating Income | $-17.9M | $-142.4M | $-20.3M | $-19.6M | $-16.5M | $-25.0M | $-21.7M | $-23.3M |
| Operating Margin | -640.7% | -62,997.3% | -8,981.4% | -8,684.5% | -7,299.1% | -10,819.5% | -994.0% | -1,895.9% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $9.2M | $-166.5M | $-18.9M | $-19.0M | $-16.2M | $-25.2M | $-21.5M | $-20.5M |
| Income Tax Expense | — | — | — | — | — | $4.0K | $10.0K | $-124.0K |
| Net Income | $9.2M | $-166.5M | $-18.9M | $-19.0M | $-16.2M | $-25.2M | $-21.5M | $-20.6M |
| Net Margin | 328.7% | -73,682.7% | -8,384.1% | -8,391.2% | -7,151.8% | -10,890.5% | -985.0% | -1,675.3% |
| EPS (Basic) | $0.83 | $-7.04 | $-4.51 | $-0.18 | $-0.19 | $-0.43 | $-0.30 | $-1.00 |
| EPS (Diluted) | $0.82 | $-7.04 | $-4.51 | $-0.18 | $-0.19 | $-0.43 | $-0.30 | $-1.00 |
| Shares Outstanding (Basic) | 8.2M | 7.8M | 4.2M | 104.5M | 84.2M | 58.0M | 555.8M | 28.4M |
| Shares Outstanding (Diluted) | 8.4M | 7.8M | 4.2M | 104.5M | 84.2M | 58.0M | 555.8M | 28.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |